Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Best Vitelliform Macular Dystrophy in a 6-Year-Old Child

Chhablani, Jay; Jalali, Subhadra

doi:10.5301/ejo.5000095

Cited by 27 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869] The years between 2007-10, being populated largely by case reports and occasional case series detailing the use of anti-VEGF agents in treating CNVM of other etiology, and retinopathy of prematurity[41] (2007), AMD[3] and adjunct to trabeculectomy[44] (2008). We can see a trend towards randomized case-control studies comparing different anti-VEGF agents, the use of combination treatments in AMD and other diseases since 2011 onwards.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Changing paradigms of anti-VEGF in the Indian scenario

Shanmugam

2014

Indian J Ophthalmol

View full text Add to dashboard Cite

Anti-vascular endothelial growth factors (VEGF) agents have revolutionized the treatment of retinal diseases. Use of anti-VEGF agents in the Indian Scenario present some unique challenges considering the absence of compounding pharmacies, poor penetrance of health insurance and limited affordability of the citizens of a developing economy. To study the changing paradigms of anti-VEGF use in the Indian scenario, all articles published by Indian authors, data from web-based surveys amongst Indian vitreo-retinal specialists were reviewed. In the paucity of compounding pharmacies in India, fractionation and injection techniques differ from those of developed countries. Frequent anti-VEGF monotherapy offers the best anatomical and visual results, but economics of scale do not allow the same in the Indian scenario, resulting in PRN dosing and combination of anti-VEGF with laser photocoagulation, being the commonly employed treatment protocols.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Case reports documenting the use of bevacizumab, ranibizumab and combination treatments such as anti-VEGF agents with photodynamic therapy have been published from India for the following indications:[222324252627282930313233343536373839]…”

Section: Resultsmentioning

confidence: 99%

Changing paradigms of anti-VEGF in the Indian scenario

Shanmugam

2014

Indian J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…While there is no prophylaxis or treatment, per se, for Best disease, these patients should be monitored by an ophthalmologist. Yearly examinations are critical for helping to prevent the development of amblyopia, for identifying and treating commonly co-occurring conditions such as hyperopia and angle closure glaucoma, and for identifying CNVM formation and treating it, most commonly with intravitreal anti-VEGF (vascular endothelial growth factor) injections [54][55][56][57][58][59][60]. Furthermore, patients should be educated on the warning signs of CNVM, decreased vision or increased metamorphopsia, which should provoke a more urgent examination.…”

Section: Best Diseasementioning

confidence: 99%

Pediatric genetic macular and choroidal diseases

Bergman

Nallasamy

2015

J Pediatr Genet

View full text Add to dashboard Cite

Genetic diseases of the macula and choroid have various inheritance patterns and varying degrees of impact on vision. Herein, we review the literature including most recent advances in the understanding of the genetics of these diseases. Although many of these disorders have limited treatment options, knowledge of inheritance patterns can aid in early detection and with close monitoring can help the ophthalmologist preserve as much vision as possible (for example with early treatment of choroidal neovascularization).

show abstract

“…Anti-VEGF (vascular endothelial growth factor) agents such as bevacizumab are used increasingly to treat individuals with choroidal neovascularization (CNV) [63]. Intravitreal bevacizumab appears to be a promising and cost-effective modality of treatment in CNV associated with BVD with good visual recovery [63].…”

Section: Treatmentmentioning

confidence: 99%

Best vitelliform macular dystrophy: literature review

Būdienė

Liutkevičienė²,

Žaliūnienė

2014

Open Medicine

View full text Add to dashboard Cite

AbstractBest vitelliform macular dystrophy (BVD) is a slowly progressive form of macular dystrophy. In most cases this disease begins in childhood although sometimes it can develop in later age. The diagnosis of BVD is based on family history, clinical and electrophysiological findings. Clinical signs are variable, yet the majority of patients have a typical yellow yolk-like macular lesion in the eye fundus. Lesions are usually bilateral, but in rare cases can be unilateral. Atrophy of the macula may develop after many years. The mutations responsible for Best vitelliform macular dystrophy are found in a gene called VMD2, which encodes a transmembrane protein named bestrophin-1 (hBest1) that is a Ca2+-sensitive chloride channel. Most reported cases causing the disease are in exons 2, 4, 6 and 8 in patients with BVD. In this article we discuss the etiology of Best’s vitelliform macular dystrophy, clinical presentation, diagnostics, genetic and current treatment possibilities.

show abstract

Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Best Vitelliform Macular Dystrophy in a 6-Year-Old Child

Abstract: Intravitreal bevacizumab appears to be a promising and cost-effective modality of treatment in CNV associated with BVMD with good visual recovery.

Cited by 27 publications

References 8 publications

Changing paradigms of anti-VEGF in the Indian scenario

Changing paradigms of anti-VEGF in the Indian scenario

Pediatric genetic macular and choroidal diseases

Best vitelliform macular dystrophy: literature review

Contact Info

Product

Resources

About